2024 年至 2031 年过敏免疫疗法市场（按过敏原类型、年龄层、免疫疗法类型、通路和地区划分）

过敏免疫疗法市场评估 - 2024-2031

2023 年过敏免疫治疗市场规模价值 20.8 亿美元，预计到 2031 年将成长 38.7 亿美元，预测期内复合年增长率为 8.10%。由于过敏性鼻炎、气喘、食物过敏等过敏性疾病的发生率不断上升，过敏免疫治疗市场正在不断扩大。随着越来越多的人寻求有效的长期治疗方法，免疫疗法优于标准药物的趋势明显。对于希望缓解症状但又不想持续使用抗组织胺或皮质类固醇的人来说尤其如此。

此外，过敏原特异性免疫治疗产品和给药方法（包括舌下片和注射）的进步正在提高患者的治疗可及性和依从性。人们对免疫疗法益处的认识不断提高以及医疗专业人士的推荐正在推动市场扩张。随着对个人化医疗的日益重视，过敏免疫治疗产业预计在未来几年将大幅成长。

过敏免疫疗法市场定义/概述

过敏免疫疗法是一种旨在降低对过敏原的敏感性并长期缓解过敏症状的治疗方法。特定的过敏原透过皮下给药（过敏原免疫疗法）或以舌下片或静脉注射的形式逐渐增加剂量。这种机制使免疫系统对过敏原产生耐受性，从而减轻过敏反应的严重程度。

它透过逐渐降低免疫系统对某些过敏原的敏感性来治疗过敏性疾病。透过注射（皮下免疫疗法）或舌下片引入控制量的过敏原。这种方法可以随着时间的推移减轻过敏反应的严重程度，并在治疗结束后提供长期缓解。过敏免疫疗法有利于治疗过敏性鼻炎、气喘和某些食物过敏等疾病，改善患者的生活品质并减少药物使用。

过敏免疫疗法的未来很可能围绕着个人化治疗技术展开，该技术利用基因和生物标记数据为特定患者定製药物。微针和穿戴式装置等创新的药物输送系统可望提高患者的依从性和舒适度。此外，对新的过敏原来源和药物组合的研究可能会扩大治疗选择。

医疗专业人员和患者的意识不断提高如何影响过敏免疫治疗市场的成长？

医疗专业人士和患者的意识不断提高，推动了过敏免疫治疗市场的成长。越来越多的医疗保健专业人士认识到免疫疗法相对于传统过敏药物的长期益处，并正在推广免疫疗法作为可行的过敏治疗选择。随着人们对免疫疗法的有效性和安全性的认知度不断提高，临床实践也发生了变化，皮下免疫疗法(SCIT) 和舌下免疫疗法(SLIT) 等疗法的接受度也不断提高。促进了市场的成长。

从患者的角度来看，人们越来越认识到过敏免疫疗法能够提供长期的舒适感，而不仅仅是暂时缓解症状，这促使对这些疗法的需求增加。患者越来越瞭解自己的选择，并且更有可能选择个人化的长期过敏治疗。这种不断增长的需求，加上医疗保健专业人士的建议，正在推动免疫疗法的采用并扩大整个市场。

高昂的治疗费用是否限制了过敏免疫治疗市场的发展？

治疗费用高是过敏免疫治疗市场的一个主要障碍，限制了患者接受治疗的机会。过敏免疫治疗，尤其是皮下免疫治疗（SCIT），需要数年多次治疗，导致患者的治疗费用高。在许多地区，此类治疗的保险覆盖范围可能有限或不存在，需要患者支付现金。儘管这种治疗方法可以长期缓解慢性过敏问题，但许多人因其高昂的费用而却步。

此外，免疫疗法的前期和经常性成本较高，限制了其应用，特别是在低收入地区和医疗资源不足的国家。对于资金紧张的医疗保健系统来说，为大规模免疫疗法计画分配资源可能并不实际，这进一步限制了市场扩张。因此，过敏的盛行率不断上升，儘管免疫疗法的疗效已得到证实，但成本仍然是广泛使用这些治疗方法的重大障碍。

目录

第 1 章全球过敏免疫治疗市场：简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 第一次面试
• 资料来源列表

第 4 章 过敏免疫疗法的全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第5章全球过敏免疫治疗市场（依过敏原类型划分）

• 概述
• 季节性过敏原
• 常年过敏原

第6章 全球过敏免疫治疗市场（依年龄层划分）

• 概述
• 儿童
• 成人

第7章 全球过敏免疫疗法市场（依免疫疗法类型）

• 概述
• 皮下免疫治疗 (SCIT)
• 舌下免疫治疗（SLIT）

第8章全球过敏免疫治疗市场（依通路）

• 医院药房
• 零售药局
• 网路药局

第 9 章全球过敏免疫治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 10 章全球过敏免疫治疗市场：竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第 11 章 公司简介

• ALK-Abello A/S
• Stallergenes Greer plc
• Allergy Therapeutics plc
• Aimmune Therapeutics, Inc.
• DBV Technologies SA
• HAL Allergy Group
• Biomay AG
• Circassia Pharmaceuticals plc
• Immunomic Therapeutics, Inc.
• Anergis

第 12 章 重大进展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 13 章附录

• 相关研究

Allergy Immunotherapy Market Valuation - 2024-2031

Allergy Immunotherapy Market size was valued at USD 2.08 Billion in 2023 and is projected to grow USD 3.87 Billion by 2031, exhibiting a CAGR of 8.10% during the forecast period. The Allergy Immunotherapy Market is expanding due to the increasing frequency of allergic illnesses such as allergic rhinitis, asthma, and food allergies. As more people seek effective, long-term treatment alternatives, the preference for immunotherapy over standard drugs is becoming clear. This is especially true for people who want to relieve their symptoms without having to use antihistamines or corticosteroids all the time.

Furthermore, advances in allergen-specific immunotherapy products and administration modalities such as sublingual tablets and injections, are improving patient access and adherence. Increasing awareness of immunotherapy's benefits combined with recommendations from healthcare experts is driving market expansion. With an emphasis on personalized medication, the allergy immunotherapy industry is expected to grow significantly in the coming years.

Allergy Immunotherapy Market: Definition/ Overview

Allergy immunotherapy is a treatment that aims to lower sensitivity to allergens resulting in long-term relief from allergy symptoms. It entails gradually administering increasing doses of certain allergens, either via subcutaneous injections (allergen immunotherapy) or sublingual tablets/drops. This mechanism helps the immune system develop tolerance to allergens reducing the severity of allergic reactions.

It is used to treat allergy diseases by progressively reducing the immune system's sensitivity to specific allergens. It entails the introduction of allergens in controlled dosages by injections (subcutaneous immunotherapy) or sublingual pills. This approach reduces the severity of allergic reactions over time and can provide long-term relief, even after therapy is completed. Allergy immunotherapy is beneficial for illnesses such as allergic rhinitis, asthma, and specific food allergies enhancing patients' quality of life and lowering drug use.

The future of allergy immunotherapy will center on personalized treatment techniques that use genetic and biomarker data to adapt medicines to specific patients. Innovative drug delivery systems, such as microneedles and wearable devices are expected to improve patient compliance and comfort. Furthermore, studies on new allergen sources and combination medicines will expand therapy choices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How has the Rising Awareness among Healthcare Professionals and Patients Impacted the Growth of the Allergy Immunotherapy Market?

Rising awareness among healthcare professionals and patients has accelerated the growth of the Allergy Immunotherapy Market. As more healthcare practitioners recognize the long-term benefits of immunotherapy over traditional allergy medications, they are more likely to promote it as a viable allergy management option. This shift in clinical practice, fuelled by improved education on the efficacy and safety of immunotherapy has resulted in increased acceptance of therapies such as Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), hence contributing to market growth.

From the patient's perspective, a rising understanding of allergy immunotherapy's ability to provide long-term comfort, rather than just temporary symptom relief has resulted in increased demand for these therapies. As patients become more aware of their alternatives, they are more likely to choose personalized, long-term allergy treatments. This rising demand combined with professional endorsements from healthcare practitioners has pushed the adoption of immunotherapy propelling total market expansion.

How Does the High Cost of Treatment Act as a Restraint in the Allergy Immunotherapy Market?

The high cost of treatment is a significant barrier in the Allergy Immunotherapy Market limiting patient access to care. Allergy immunotherapy, particularly Subcutaneous Immunotherapy (SCIT) needs several sessions over several years which can be costly for patients. In many areas, insurance coverage for such therapies may be limited or absent requiring patients to pay out of cash. Even though the therapy provides long-term relief for chronic allergy problems, many people are put off by the cost.

Furthermore, the high initial and recurring costs associated with immunotherapy limit its accessibility, particularly in low-income regions or nations with inadequate healthcare resources. Allocating resources for extensive immunotherapy programs may be impractical for healthcare systems with limited finances, further restricting market expansion. As a result, despite the increasing incidence of allergies and the established efficacy of immunotherapy, cost remains a significant barrier to the wider use of these treatments.

Category-Wise Acumens

How Does the Method of Allergen Exposure in SCIT Contribute to the Long-Term Efficacy of Treatment for Allergic Diseases?

Subcutaneous Immunotherapy (SCIT) dominates the Allergy Immunotherapy Market due to its long-standing efficacy and comprehensive strategy. SCIT includes injecting allergen extracts directly under the skin allowing for controlled exposure and eventual desensitization of the immune system to specific allergens. This approach has been widely researched and shown helpful for a variety of allergens, notably pollen, dust mites, and animal dander making it a popular choice among both patients and healthcare providers looking for long-term relief.

Furthermore, SCIT provides a well-defined treatment regimen with established protocols resulting in predictable dose and response. The inclusion of multiple allergens in SCIT formulations allows for more personalized therapy options for patients which improves compliance and satisfaction. While sublingual immunotherapy (SLIT) is gaining popularity due to its simplicity of administration, SCIT remains dominant due to its proven track record, strong clinical data, and allergists' preference for its comprehensive approach to addressing allergic diseases.

How Does the Preparation of Personalized Immunotherapy Regimens in Hospital Pharmacies Affect Patient Adherence to Treatment Plans?

Hospital pharmacies dominate the allergy immunotherapy industry because they have access to a wide choice of specialized drugs and treatment alternatives. These pharmacies are ready to prepare and distribute personalized immunotherapy regimens such as allergy injections and sublingual pills, based on patient needs. The presence of allergists and immunologists in hospital settings promotes teamwork, resulting in better patient care and monitoring throughout the therapy process. This integrated strategy guarantees that patients receive timely and effective medicines which leads to better outcomes.

Furthermore, hospital pharmacies benefit from established partnerships with pharmaceutical producers allowing them to obtain the most recent immunotherapy medicines and updates on treatment methods. As hospitals implement multidisciplinary care models, coordination among chemists, healthcare professionals, and patients improves. This comprehensive strategy not only improves patient adherence to medication but also creates a supportive atmosphere for continued education and follow-up reinforcing hospital pharmacies' role in the Allergy Immunotherapy Market.

Country/Region-wise Acumens

How do Reimbursement Policies Influence Patient Access to Allergy Immunotherapy in the North American Region?

North America dominates the Allergy Immunotherapy Market, owing to the increasing prevalence of allergic illnesses like allergic rhinitis and asthma which drives demand for better treatment alternatives. The region benefits from excellent healthcare facilities, extensive research programs, and a thriving pharmaceutical sector. Major corporations are significantly investing in novel medicines such as subcutaneous and sublingual immunotherapy, to meet the rising patient population. Furthermore, as healthcare practitioners and patients become more aware of allergic disorders, acceptance and usage of immunotherapy treatments have increased.

Furthermore, supporting regulatory frameworks and favorable reimbursement policies in the United States promote market expansion. The Food and Drug Administration (FDA) has approved several immunotherapy medicines, increasing their market penetration. North American healthcare systems prioritize personalized medicine and patient-centered approaches which encourages the use of allergy immunotherapy. As a result, the region is well-positioned to sustain its market leadership opening the path for ongoing breakthroughs in treatment techniques.

How are Changing Lifestyles and Urbanization Impacting the Prevalence of Asthma and Allergic Rhinitis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the Allergy Immunotherapy Market owing to rising allergy incidence, increased healthcare awareness, and considerable investment in R&D. Urbanisation and changing lifestyles have contributed to an increase in allergy disorders such as asthma and allergic rhinitis creating a larger demand for effective treatments. As more people become aware of the benefits of immunotherapy, healthcare providers are more likely to recommend it resulting in increased market growth.

Furthermore, supportive government initiatives and partnerships with pharmaceutical companies improve access to allergy treatments and advances. The region's increasing middle class is pushing up healthcare spending allowing for the adoption of modern therapeutic choices. Furthermore, the expansion of healthcare infrastructure and the growing number of allergists and immunologists in countries such as China and India are key drivers of market growth. Overall, the combination of increased allergies and greater healthcare access has positioned Asia Pacific as a market leader in allergy immunotherapy.

Competitive Landscape

The Allergy Immunotherapy Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Allergy Immunotherapy Market include:

ALK-Abello A/S, Stallergenes Greer plc, Allergy Therapeutics plc, Merck & Co., Inc. (known as MSD outside of the United States and Canada), Aimmune Therapeutics, Inc., DBV Technologies SA, HAL Allergy Group, Biomay AG, Circassia Pharmaceuticals plc, Immunomic Therapeutics, Inc., Anergis, ASIT Biotech, and Adamis Pharmaceuticals Corporation.

Latest Developments

In January 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), two clinical-stage immunotherapeutic companies, announced a collaboration to develop a novel oral mucosal allergy immunotherapy for treating peanut allergy.

In October 2023, ALK reported the successful completion of Itulatek's phase 3 trial for treating allergy rhinoconjunctivitis caused by tree pollen.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ALLERGY IMMUNOTHERAPY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ALLERGY IMMUNOTHERAPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY ALLERGEN TYPE

• 5.1 Overview
• 5.2 Seasonal Allergens
• 5.3 Perennial Allergens

6 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY AGE GROUP

• 6.1 Overview
• 6.2 Children
• 6.3 Adults

7 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY TYPE OF IMMUNOTHERAPY

• 7.1 Overview
• 7.2 Subcutaneous Immunotherapy (SCIT)
• 7.3 Sublingual Immunotherapy (SLIT)

8 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

• 8.1 Hospital Pharmacies
• 8.2 Retail Pharmacies
• 8.3 Online Pharmacies

9 GLOBAL ALLERGY IMMUNOTHERAPY MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL ALLERGY IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 ALK-Abello A/S
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Stallergenes Greer plc
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Allergy Therapeutics plc
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Aimmune Therapeutics, Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 DBV Technologies SA
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 HAL Allergy Group
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Biomay AG
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Circassia Pharmaceuticals plc
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Immunomic Therapeutics, Inc.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Anergis
  • 11.11.1 Overview
  • 11.11.2 Financial Performance
  • 11.11.3 Product Outlook
  • 11.11.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research